World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF KIDNEY CANCER USING SIMILAR MOLECULE - CABOZANTINIB S-MALATE

Dr. Syed Ahmed Hussain*, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa, Raheem Unnisa Shaik and Nazneen

ABSTRACT

Aim: This study aims to investigate the cytotoxic effects of Cabozantinib S-malate on kidney cancer cells using a
series of in vitro assays. Objective: The primary objective is to assess the dose-dependent inhibition of kidney
cancer cell viability by Cabozantinib S-malate and compare its activity with the control compound, Everolimus.
Research: Kidney cancer cells were treated with increasing concentrations (1 μM, 5 μM, and 10 μM) of
Cabozantinib S-malate. The MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH Cytotoxicity assays were used to
evaluate cell viability. The MTT assay revealed a reduction in cell viability from 83% at 1 μM to 35% at 10 μM.
Similar trends were observed in the CellTiter-Glo, Alamar Blue, and SRB assays, which further confirmed the
dose-dependent inhibition. However, the LDH Cytotoxicity Assay showed a notable increase in cell viability
(79.9%) at 10 μM, suggesting potential necrotic pathways or cell membrane disruption. Conclusion: Cabozantinib
S-malate demonstrated a potent dose-dependent cytotoxic effect against kidney cancer cells across multiple assays.
Further investigation is required to explore its specific mechanisms of action and to understand its
pharmacodynamic properties at higher concentrations.

[Full Text Article]   [Download Certificate]